Sanofi pushes for reconsideration in US antitrust case over injectable insulin
( May 6, 2026, 20:55 GMT | Official Statement) -- MLex Summary: Sanofi-Aventis filed a reply in support of its request for reconsideration on whether Mylan can plead a bundled-discount theory of exclusion based on a bundle of products in the same product market, in an antitrust case over an injectable form of diabetes drug insulin glargine. Sanofi said Mylan’s opposition declines to defend the viability of its single-market bundling theory and tries to reshape its factual allegations, now claiming that Sanofi’s products are in separate markets, while the actual complaint alleges the opposite. See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.